Nephrogenic systemic fibrosis: incidence, associations, and effect of risk factor assessment--report of 33 cases
- PMID: 19188312
- PMCID: PMC2663356
- DOI: 10.1148/radiol.2502080498
Nephrogenic systemic fibrosis: incidence, associations, and effect of risk factor assessment--report of 33 cases
Abstract
Purpose: To describe the presentation and clinical course of patients with nephrogenic systemic fibrosis (NSF) at a large acute-care hospital, to evaluate the overall incidence of NSF, and to assess the effect of a hospital-wide policy regarding gadolinium-based contrast agent (GBCA) use on NSF incidence.
Materials and methods: A review of all cases of NSF observed at an institution from 2003 to 2008 was conducted. This HIPAA-compliant study was approved by the institutional review board. The informed consent requirement was waived. Demographics, medical history, and associated conditions were recorded. Radiologic procedures were evaluated if they were performed within 1 year prior to NSF onset. GBCA use was assessed by checking the electronic database for each procedure. The incidence of NSF was compared before and after implementation of an institutional policy designed to assess risk of NSF prior to GBCA use.
Results: All 33 patients with NSF (mean age, 49 years; age range, 15-78 years) had advanced renal failure (estimated glomerular filtration rate < 15 mL/min/1.73 m(2)) when the GBCA was injected. Twenty-six patients had severe chronic or end-stage renal disease, and seven had acute renal failure. The mean interval between contrast material injection and NSF onset was 29 days +/- 25 (standard deviation) (range, 4-112 days). The overall incidence of NSF was 36.5 cases per 100,000 gadolinium-enhanced magnetic resonance (MR) examinations between 2003 and 2006 and four cases per 100,000 gadolinium-enhanced MR examinations between 2007 and 2008 after screening for NSF risk was instituted (Fisher exact test, P = .001). Five patients developed NSF in the peritransplant period, and four underwent a catheter-based radiographic procedure with administration of a GBCA.
Conclusion: Common associations of GBCA MR imaging and NSF were acute and severe chronic renal failure and liver or renal transplantation. Screening procedures performed before MR imaging to determine which patients were at risk of developing NSF appear to reduce the incidence of this complication and further support the belief that NSF is associated with GBCA administration.
Figures
Similar articles
-
Incidence of nephrogenic systemic fibrosis after adoption of restrictive gadolinium-based contrast agent guidelines.Radiology. 2011 Jul;260(1):105-11. doi: 10.1148/radiol.11102340. Epub 2011 May 17. Radiology. 2011. PMID: 21586680
-
Nephrogenic systemic fibrosis: change in incidence following a switch in gadolinium agents and adoption of a gadolinium policy--report from two U.S. universities.Radiology. 2009 Dec;253(3):689-96. doi: 10.1148/radiol.2533090649. Epub 2009 Sep 29. Radiology. 2009. PMID: 19789233
-
Risk of nephrogenic systemic fibrosis is low in patients with chronic liver disease exposed to gadolinium-based contrast agents.J Magn Reson Imaging. 2015 May;41(5):1259-67. doi: 10.1002/jmri.24650. Epub 2014 May 9. J Magn Reson Imaging. 2015. PMID: 24811860 Free PMC article.
-
Nephrogenic systemic fibrosis: risk factors suggested from Japanese published cases.Br J Radiol. 2010 Jul;83(991):590-5. doi: 10.1259/bjr/17689538. Epub 2010 Apr 22. Br J Radiol. 2010. PMID: 20413447 Free PMC article. Review.
-
Risk of Nephrogenic Systemic Fibrosis in Patients With Stage 4 or 5 Chronic Kidney Disease Receiving a Group II Gadolinium-Based Contrast Agent: A Systematic Review and Meta-analysis.JAMA Intern Med. 2020 Feb 1;180(2):223-230. doi: 10.1001/jamainternmed.2019.5284. JAMA Intern Med. 2020. PMID: 31816007 Free PMC article.
Cited by
-
Scleroderma mimics.Curr Rheumatol Rep. 2012 Feb;14(1):39-46. doi: 10.1007/s11926-011-0220-8. Curr Rheumatol Rep. 2012. PMID: 22131103 Review.
-
Nephrogenic Systemic Fibrosis as a Complication after Gadolinium-Containing Contrast Agents: A Rapid Review.Int J Environ Res Public Health. 2021 Mar 15;18(6):3000. doi: 10.3390/ijerph18063000. Int J Environ Res Public Health. 2021. PMID: 33804005 Free PMC article. Review.
-
Metal-Based Complexes as Pharmaceuticals for Molecular Imaging of the Liver.Pharmaceuticals (Basel). 2019 Sep 16;12(3):137. doi: 10.3390/ph12030137. Pharmaceuticals (Basel). 2019. PMID: 31527492 Free PMC article. Review.
-
Seeing Better and Going Deeper in Cancer Nanotheranostics.Int J Mol Sci. 2019 Jul 16;20(14):3490. doi: 10.3390/ijms20143490. Int J Mol Sci. 2019. PMID: 31315232 Free PMC article. Review.
-
Development of a Suite of Gadolinium-Free OATP1-Targeted Paramagnetic Probes for Liver MRI.J Med Chem. 2023 May 25;66(10):6567-6576. doi: 10.1021/acs.jmedchem.2c01561. Epub 2023 May 9. J Med Chem. 2023. PMID: 37159947 Free PMC article.
References
-
- Cowper SE. Nephrogenic systemic fibrosis: the nosological and conceptual evolution of nephrogenic fibrosing dermopathy. Am J Kidney Dis 2005;46:763–765. - PubMed
-
- Kucher C, Steere J, Elenitsas R, Siegel DL, Xu X. Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis with diaphragmatic involvement in a patient with respiratory failure. J Am Acad Dermatol 2006;54(2 suppl):S31–S34. - PubMed
-
- Ting WW, Stone MS, Madison KC, Kurtz K. Nephrogenic fibrosing dermopathy with systemic involvement. Arch Dermatol 2003;139:903–906. - PubMed
-
- Daram SR, Cortese CM, Bastani B. Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis: report of a new case with literature review. Am J Kidney Dis 2005;46:754–759. - PubMed
-
- Grobner T. Gadolinium: a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 2006;21:1104–1108. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical